The Savella Pregnancy Registry (SPR)
This study is currently recruiting participants.
Verified February 2013 by INC Research
Sponsor:
INC Research
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
INC Research
ClinicalTrials.gov Identifier:
NCT01026077
First received: December 3, 2009
Last updated: February 28, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Savella Pregnancy Registry is a US based registry designed to monitor pregnancies exposed to Savella (milnacipran HCI). This is an observational, exposure-registration and follow-up registry designed primarily to estimate the prevalence of major congenital anomalies, and secondarily to estimate the prevalence of recognized spontaneous abortions, stillbirths, induced abortions, minor congenital anomalies, and any serious adverse pregnancy outcomes among pregnancies exposed to Savella as well as adverse outcomes observed during the first year of life in off-springs born from these exposed pregnancies. Live offspring are followed from birth until age one. The Savella Pregnancy Registry is sponsored by Forest Laboratories Inc. (Forest) and managed by INC Research, LLC.
| Condition |
|---|
|
Fibromyalgia |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Target Follow-Up Duration: | 1 Year |
| Official Title: | The Savella Pregnancy Registry |
Resource links provided by NLM:
Further study details as provided by INC Research:
Primary Outcome Measures:
- The primary objective is to estimate the prevalence of major congenital anomalies among off-springs of women exposed to Savella during pregnancy. [ Time Frame: January 2017 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Estimate the prevalence of spontaneous abortions, stillbirths, induced abortions, minor congenital anomalies, and adverse pregnancy outcomes. [ Time Frame: January 2017 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 350 |
| Study Start Date: | November 2009 |
| Estimated Study Completion Date: | January 2017 |
| Estimated Primary Completion Date: | January 2017 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Fibromyalgia/prospective pregnancies
Women taking Savella during pregnancy. Register prospectively, provide verbal consent.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
Women who are exposed to Savella during pregnancy.
Criteria
Inclusion Criteria:
- Females exposed to Savella during pregnancy
- Willing to provide verbal consent
- 18 y/o, US citizen
Exclusion Criteria:
- Male
- Under 18 y/o
- Females not pregnant, not exposed to savella
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01026077
Contacts
| Contact: Pamela Meador | 877-643-3010 |
Locations
| United States, North Carolina | |
| INC Research | Recruiting |
| Wilmington, North Carolina, United States, 28405 | |
| Contact: Jan McLean 910-679-1572 pregnancyregistries@incresearch.com | |
| Contact: Susan Goodlow 877.643.3010 pregnancyregistries@incresearch.com | |
Sponsors and Collaborators
INC Research
Forest Laboratories
Investigators
| Principal Investigator: | Susan Roberts, RN, PhD | Sr. Epidemiologist |
More Information
Additional Information:
No publications provided
| Responsible Party: | INC Research |
| ClinicalTrials.gov Identifier: | NCT01026077 History of Changes |
| Other Study ID Numbers: | MLN-MD-30 |
| Study First Received: | December 3, 2009 |
| Last Updated: | February 28, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by INC Research:
|
Savella pregnant savella pregnancy fibromyalgia pregnant fibromyalgia pregnancy pregnancy registry savella |
Additional relevant MeSH terms:
|
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases Milnacipran Antidepressive Agents Psychotropic Drugs Central Nervous System Agents |
Therapeutic Uses Pharmacologic Actions Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Agents Physiological Effects of Drugs Adrenergic Uptake Inhibitors Adrenergic Agents |
ClinicalTrials.gov processed this record on June 18, 2013